MedTrace Logo

Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems

NCT01261741 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 299

Last updated 2013-11-27

No results posted yet for this study

Summary

In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.

Conditions

  • Memory Disorder
  • Retention Disorder, Cognitive
  • Subjective Cognitive Impairment
  • Memory, Concentration or Attention Problems

Interventions

DRUG

Memantine

Each subject will receive memantine 10mg tablets once daily

DRUG

Placebo

Each subject will receive matching placebo tablets once daily

Sponsors & Collaborators

  • Merz Pharmaceuticals GmbH

    lead INDUSTRY

Principal Investigators

  • Merz Medical Expert · Merz Pharmaceuticals GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01261741 on ClinicalTrials.gov